Patents Examined by Lynn A. Bristol
  • Patent number: 12012443
    Abstract: Described herein are immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. Some immunomodulatory fusion proteins as described comprise a SIRP? extracellular component and hydrophobic and intracellular components comprising transmembrane and/or signaling domains of a CD28, respectively. Such fusion proteins are capable of delivering a positive or costimulatory signal in response to a binding event that in a natural setting would result in an inhibitory signal. Uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease, are also described.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: June 18, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Shannon K. Oda, Philip D. Greenberg, Thomas M. Schmitt
  • Patent number: 12011481
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM 3 and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: June 18, 2024
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Patent number: 11999790
    Abstract: This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: June 4, 2024
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni
  • Patent number: 11999801
    Abstract: The present invention relates to multispecific antibodies comprising at least three antigen binding sites wherein the third binding site is disulfide stabilized by introduction of cysteine, method for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: June 4, 2024
    Assignee: Hoffman-La Roche Inc.
    Inventors: Ulrich Brinkmann, Wolfgang Schaefer, Klaus Mayer
  • Patent number: 11993643
    Abstract: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: May 28, 2024
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventor: Jamshid Tanha
  • Patent number: 11987633
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3? (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: May 21, 2024
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterb├╝se, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
  • Patent number: 11987640
    Abstract: Mesothelin (MSLN) is expressed on pancreatic cancers, ovarian cancers and mesotheliomas. The present disclosure provides antigen-binding molecules, including anti-MSLN antibodies, and bispecific antigen-binding molecules that bind to both MSLN and a T cell antigen (e.g., CD3) and activate T cells in the presence of MSLN-expressing tumor cells. The antigen-binding molecules of this disclosure are useful for the treatment of diseases and disorders in which a MSLN-targeted immune response is desired and/or therapeutically beneficial. For example, the antigen-binding molecules of the present disclosure are useful for the treatment of various cancers, including pancreatic cancer, ovarian cancer and mesotheliomas.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: May 21, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Colin Correnti, Ashok Bandaranayake, Christopher Mehlin, James M. Olson, Soheil Meshinchi
  • Patent number: 11976136
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 7, 2024
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Patent number: 11970533
    Abstract: Antibodies binding to human claudin 18.2 (CLDN 18.2) and bispecific antibodies binding to both human CLDN 18.2 and PD-L1, pharmaceutical compositions comprising such, and methods of using such for treating target diseases including cancer.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: April 30, 2024
    Assignee: SPARX BIOSCIENCE LIMITED
    Inventors: Guidong Zhu, Jingdong Ye, Jichun Ma, Jingdong Qin, Hongyu Zhao
  • Patent number: 11965019
    Abstract: Provided herein are stabilized chimeric Fabs derived from a parent chimeric Fab having a lambda light chain. The stabilized chimeric Fabs comprise an immunoglobulin heavy chain polypeptide construct from the parent chimeric Fab, having a CH1 sequence and a VH sequence, as well as a Vlambda-Ckappa chimeric light chain construct. The Vlambda sequence of the chimeric light chain construct corresponds to that of the parent chimeric Fab, and comprises one or more stabilizing amino acid modifications that increase the thermal stability of the stabilized chimeric Fab compared to the parent chimeric Fab. The stabilized Fabs are useful as therapeutic polypeptides, or can be used to prepare antibody constructs in other formats. The stabilized chimeric Fabs may also be useful generally to increase the stability of antibodies having lambda light chains.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 23, 2024
    Assignee: ZYMEWORKS BC INC.
    Inventors: Dunja Urosev, Yang-Chieh Chou
  • Patent number: 11964998
    Abstract: The present invention relates to a method for purifying anti-IL-6 receptor antibodies from a sample comprising said antibodies and impurities, through the use of a three-chromatographic columns procedure, including a chromatography on Fluorapatite-containing resin. The invention is also concerned with pharmaceutical compositions comprising the purified antibodies obtainable by the process of the invention.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: April 23, 2024
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Harry-James Sutter, Xavier Le Saout
  • Patent number: 11958913
    Abstract: The present invention relates to a mutant polypeptide linker for preparing multispecific antibodies, multispecific antibodies, and methods for producing multispecific antibodies.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: April 16, 2024
    Assignee: BIOMUNEX PHARMACEUTICALS
    Inventors: Eugene Zhukovsky, Olivier Leger
  • Patent number: 11958902
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: April 16, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • Patent number: 11959118
    Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: April 16, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Terrance A. Stadheim, Dongxin Zha, Liming Liu
  • Patent number: 11952424
    Abstract: The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence. The invention also relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein at least one additional binding domain comprises a CH1 region and is connected to the base antibody portion by said linker, linking a variable region of the base antibody portion and the CH1 region, and wherein the multivalent antibody binds to at least three different epitopes.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 9, 2024
    Assignee: merus n.v.
    Inventors: Cornelis Adriaan de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
  • Patent number: 11944648
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Grant
    Filed: August 25, 2023
    Date of Patent: April 2, 2024
    Assignees: The Regents of the University of California, Seattle Children's Hospital
    Inventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
  • Patent number: 11944643
    Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 2, 2024
    Assignee: CELLECTIS SA
    Inventors: Julianne Smith, Philippe Duchateau, Murielle Derrien
  • Patent number: 11945873
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: April 2, 2024
    Assignee: GENSUN BIOPHARMA, INC.
    Inventors: Jackie Sheng, Bo Liu, Margaret Karow
  • Patent number: 11926667
    Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: March 12, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Sanjaya Singh, Iqbal S. Grewal, Michael Riis Hansen
  • Patent number: 11919970
    Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 5, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons